ClinicalTrials.gov
ClinicalTrials.gov Menu

Lipitor In The Prevention Of Stroke, For Patients Who Have Had A Previous Stroke (SPARCL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00147602
Recruitment Status : Completed
First Posted : September 7, 2005
Last Update Posted : April 22, 2015
Sponsor:
Information provided by:
Pfizer

Brief Summary:
To determine whether Lipitor reduces stroke, compared to placebo in patients who have had a previous stroke or transient ischemic attack.

Condition or disease Intervention/treatment Phase
Cardiovascular Disease Drug: atorvastatin Phase 4

Study Type : Interventional  (Clinical Trial)
Enrollment : 4732 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Double-Blind, Randomized, Placebo- Controlled Study Of Atorvastatin As Prevention Of Cerebrovascular Events In Patients With A Previous Transient Ischemic Attack (TIA) Or Stroke
Study Start Date : November 1998
Study Completion Date : November 2005

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. Time to occurrence of fatal or non-fatal stroke

Secondary Outcome Measures :
  1. Time to occurrence of an acute coronary event, consisting of cardiac death, nonfatal myocardial infarction, resuscitated cardiac arrest or unstable angina.
  2. Time to occurrence of a cerebrovascular event, defined as fatal or nonfatal stroke or TIA.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Previous stroke or TIA

Exclusion Criteria:

  • coronary heart disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00147602


  Show 130 Study Locations
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer

Publications of Results:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

ClinicalTrials.gov Identifier: NCT00147602     History of Changes
Other Study ID Numbers: 0981-342
A2581138
First Posted: September 7, 2005    Key Record Dates
Last Update Posted: April 22, 2015
Last Verified: April 2015

Additional relevant MeSH terms:
Cardiovascular Diseases
Atorvastatin Calcium
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors